UPDATE: JPMorgan Starts OraSure Technologies (OSUR) at Neutral

(updating comment)

JPMorgan analyst Tycho Peterson initiates coverage on OraSure Technologies (NASDAQ: OSUR) with a Neutral rating and a price target of $18.00.

The analyst comments "OSUR is a leader in the development of diagnostic assays for infectious disease and molecular collection devices for the genome and microbiome. The legacy business leverages the OraQuick rapid diagnostic platform via oral fluid for POC diagnosis of infectious disease, such as HIV, HCV and COVID-19. Additionally, through the DNA Genotek (DNAG) subsidiary, OSUR provides kits for the collection, stabilization, transportation and storage of human and microbial DNA/RNA. DNAG’s flagship product, Oragene, is best known as the saliva DNA sample collection kit used by 23andMe. While the base business has potential tailwinds from COVID-19 Dx solutions and recent acquisitions in the DNAG business could offset weakness in the consumer genomics market, we see these opportunities as priced into valuation, resulting in our Neutral rating."

For an analyst ratings summary and ratings history on OraSure Technologies click here. For more ratings news on OraSure Technologies click here.

Shares of OraSure Technologies closed at $14.05 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker